FDA Initiates Class III Recall for Slate Run Pharmaceuticals' Eptifibatide Injection Due to Critical Labeling Error
Slate Run Pharmaceuticals, LLC faces an FDA Class III recall for its Eptifibatide Injection (75 mg/100 mL) due to a critical labeling error. The carton incorrectly specifies "weight-adjusted bolus dosing" instead of the approved "weight-adjusted infusion." This voluntary, firm-initiated recall, D-0343-2026, impacts nationwide distribution, signaling heightened regulatory scrutiny on labeling accuracy and supply chain oversight for generic injectables.
FDA Regulatory Action: Labeling Deficiency Triggers Eptifibatide Recall
The U.S. Food and Drug Administration (FDA) has classified a voluntary, firm-initiated recall (D-0343-2026) by Slate Run Pharmaceuticals, LLC for its Eptifibatide Injection, 75 mg/100 mL vial. Initiated on February 12, 2026, this Class III recall addresses a critical labeling error on the product carton. Specifically, the label incorrectly states "for weight-adjusted bolus dosing," deviating from the FDA-approved instruction of "for weight-adjusted infusion." This discrepancy, while not immediately life-threatening, represents a significant regulatory lapse that could lead to incorrect administration of a vital antiplatelet agent. For procurement directors and regulatory affairs heads, this event underscores the imperative for meticulous label verification, especially for high-risk injectable medications. The product, distributed nationwide within the USA, is manufactured by Hainan Poly Pharm. Co., Ltd. in Haikou, Hainan Province, China, and distributed by Slate Run Pharmaceuticals, LLC from Columbus, Ohio. The affected product carries NDC Slate Run Carton Label: 70436-027-80 and NDC ProRx Carton Label: 70436-163-80. This ongoing recall demands immediate action from healthcare providers and distributors to ensure patient safety and compliance with approved dosing regimens.
Operational Impact: Supply Chain Vulnerabilities for Eptifibatide
This recall of Eptifibatide Injection exposes potential vulnerabilities within the pharmaceutical supply chain, particularly concerning products manufactured overseas and distributed in the U.S. Slate Run Pharmaceuticals, LLC, operating from Columbus, Ohio, serves as the distributor for this product, which is manufactured by Hainan Poly Pharm. Co., Ltd. in China. The reliance on a single overseas manufacturing site for a critical intravenous drug like Eptifibatide, a platelet aggregation inhibitor, introduces inherent risks. Supply chain VPs must recognize that such a setup necessitates stringent oversight of contract manufacturing organizations (CMOs) to prevent quality and labeling deviations. A labeling error originating from the manufacturer, despite being distributed by a U.S. entity, can lead to widespread product disruption and significant financial implications, including product retrieval costs, potential penalties, and reputational damage. This event highlights the need for robust quality agreements, continuous auditing of CMOs, and potentially a diversified sourcing strategy to mitigate risks associated with single-source dependency, especially for essential generic drugs like Eptifibatide (unii: NA8320J834).
Market Implications for Antiplatelet Therapies and Generic Supply
Eptifibatide, a crucial antiplatelet aggregation inhibitor (pharm_class_epc: Platelet Aggregation Inhibitor [EPC]), is widely used in managing acute coronary syndromes and during percutaneous coronary intervention. The recall of Slate Run Pharmaceuticals' Eptifibatide Injection (ANDA209864) due to a labeling error could create temporary supply chain disruptions and shift market dynamics for generic versions of this drug. Procurement directors should immediately assess their current stock levels and alternative sourcing options for Eptifibatide to ensure continuity of patient care. While this is a Class III recall, indicating a low probability of serious adverse health consequences, any disruption in the supply of such a critical medication can have significant operational impacts on hospitals and clinics. Business development executives should monitor competitors who supply Eptifibatide or similar antiplatelet agents, as they may experience increased demand. This incident underscores the competitive yet fragile nature of the generic injectable market, where even minor regulatory non-compliance can trigger widespread market adjustments and necessitate rapid strategic responses from buyers and alternative suppliers.
Navigating Regulatory Scrutiny and Enhanced Compliance Requirements
This Class III recall, initiated by Slate Run Pharmaceuticals but classified by the FDA, serves as a clear indicator of the agency's unyielding focus on labeling accuracy and overall product quality, even for generic medications. For regulatory affairs heads, this incident emphasizes the critical importance of a robust quality management system that extends beyond manufacturing to encompass all aspects of product lifecycle, including labeling and distribution oversight. The distinction between "weight-adjusted bolus dosing" and "weight-adjusted infusion" is a clinical detail that, if miscommunicated, could lead to suboptimal patient outcomes. Companies must ensure that all product information, from initial submission (ANDA209864) to final packaging, aligns precisely with approved specifications. The ongoing status of this recall (D-0343-2026) means that Slate Run Pharmaceuticals will remain under FDA scrutiny, potentially facing further inspections or enforcement actions. Proactive investment in comprehensive labeling control, rigorous change management, and thorough review processes is essential to mitigate future regulatory risks and avoid costly recalls and potential Warning Letters.
Broader Regulatory Landscape and Parallel Enforcement Trends
The recall of Slate Run Pharmaceuticals' Eptifibatide Injection occurs within a broader context of heightened FDA enforcement and scrutiny across the chemical and life sciences industry. Recent parallel events highlight a consistent regulatory focus on quality and compliance. For instance, Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures in June 2026, and Spectra Medical Devices' Lidocaine HCl Injection experienced a similar Class II recall for sterility deficiencies. Even non-sterile products like Guardian Drug Co. Inc.'s Calcium Carbonate Antacids faced nationwide Class II recalls for metallic contamination. These incidents, occurring concurrently with Slate Run's labeling issue, demonstrate that the FDA is actively monitoring and enforcing quality standards across a diverse range of pharmaceutical products and manufacturing processes. For senior decision-makers, this trend signals an environment where regulatory non-compliance, regardless of its classification severity, is met with swift action. Companies must adopt a holistic approach to quality and regulatory affairs, anticipating increased audits and the need for robust, end-to-end quality systems to navigate this stringent landscape effectively.